Jin Joo Park1, Chan Joo Lee2, Sung-Ji Park3, Jin-Oh Choi3, Seonghoon Choi4, Seong-Mi Park5, Eui Young Choi6, Eung Ju Kim7, Byung-Su Yoo8, Seok-Min Kang2, Myung Hee Park9, Jungkuk Lee9, Dong-Ju Choi1. 1. Division of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea. 2. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 3. Department of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, Korea. 4. Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea. 5. Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. 6. Department of Internal Medicine, Yonsei University Gangnam Severance Hospital, Seoul, Korea. 7. Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. 8. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. 9. Data Science Team, Hanmi Pharm. Co., Ltd., Seoul, Korea.
Abstract
Background and Objectives: Heart failure (HF) is a disease with high morbidity and mortality. With ageing society and increasing prevalence of risk factors of HF, the prevalence of HF is expected to increase, as well. In this official report of the Korean Society of Heart Failure the epidemiology of HF in Korea is presented. Methods: The data of Korean National Health Insurance big data, the Korean Heart Failure (KorHF) and the Korean Acute Heart Failure (KorAHF) registries have been used. Results: In 2018, the prevalence, incidence, mortality of HF patients, and mortality due to HF were 2,261, 579, 245, and 10.4 per 100.000 persons, respectively. Regarding the temporal trend, there was a continuous increase in HF prevalence (0.77% in 2002, 1.48% in 2013, and 2.24% in 2018) and HF related deaths. The most common etiology for HF was ischemic origin, and the dominant subtype was HF with reduced ejection fraction (EF), defined as EF ≤40%. Of these, 77.6%, 58.0%, and 55.1% received renin-angiotensin-system inhibitors (angiotensin-converting-enzyme inhibitors or angiotensin-receptor-blockers), beta-blockers, and aldosterone-antagonists, respectively. In 2018, 1,542 implantable cardiac defibrillators and 272 cardiac resynchronization therapy devices were implanted, and 176 patients received heart transplantation. With improvement of pharmacologic and non-pharmacological therapy, the survival time of HF has been improving in the last 2 decades; nonetheless, it is associated with enormous increase in medical costs. Conclusions: The prevalence of HF has been increasing in Korea. With improvement of therapy, the prognosis of HF has been improving, too. Nonetheless, appropriate interventions are necessary to prevent HF.
Background and Objectives: Heart failure (HF) is a disease with high morbidity and mortality. With ageing society and increasing prevalence of risk factors of HF, the prevalence of HF is expected to increase, as well. In this official report of the Korean Society of Heart Failure the epidemiology of HF in Korea is presented. Methods: The data of Korean National Health Insurance big data, the Korean Heart Failure (KorHF) and the Korean Acute Heart Failure (KorAHF) registries have been used. Results: In 2018, the prevalence, incidence, mortality of HF patients, and mortality due to HF were 2,261, 579, 245, and 10.4 per 100.000 persons, respectively. Regarding the temporal trend, there was a continuous increase in HF prevalence (0.77% in 2002, 1.48% in 2013, and 2.24% in 2018) and HF related deaths. The most common etiology for HF was ischemic origin, and the dominant subtype was HF with reduced ejection fraction (EF), defined as EF ≤40%. Of these, 77.6%, 58.0%, and 55.1% received renin-angiotensin-system inhibitors (angiotensin-converting-enzyme inhibitors or angiotensin-receptor-blockers), beta-blockers, and aldosterone-antagonists, respectively. In 2018, 1,542 implantable cardiac defibrillators and 272 cardiac resynchronization therapy devices were implanted, and 176 patients received heart transplantation. With improvement of pharmacologic and non-pharmacological therapy, the survival time of HF has been improving in the last 2 decades; nonetheless, it is associated with enormous increase in medical costs. Conclusions: The prevalence of HF has been increasing in Korea. With improvement of therapy, the prognosis of HF has been improving, too. Nonetheless, appropriate interventions are necessary to prevent HF.
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Biykem Bozkurt; Andrew Js Coats; Hiroyuki Tsutsui; Magdy Abdelhamid; Stamatis Adamopoulos; Nancy Albert; Stefan D Anker; John Atherton; Michael Böhm; Javed Butler; Mark H Drazner; G Michael Felker; Gerasimos Filippatos; Gregg C Fonarow; Mona Fiuzat; Juan-Esteban Gomez-Mesa; Paul Heidenreich; Teruhiko Imamura; James Januzzi; Ewa A Jankowska; Prateeti Khazanie; Koichiro Kinugawa; Carolyn S P Lam; Yuya Matsue; Marco Metra; Tomohito Ohtani; Massimo Francesco Piepoli; Piotr Ponikowski; Giuseppe M C Rosano; Yasushi Sakata; Petar SeferoviĆ; Randall C Starling; John R Teerlink; Orly Vardeny; Kazuhiro Yamamoto; Clyde Yancy; Jian Zhang; Shelley Zieroth Journal: J Card Fail Date: 2021-03-01 Impact factor: 5.712
Authors: Nathalie Conrad; Andrew Judge; Jenny Tran; Hamid Mohseni; Deborah Hedgecott; Abel Perez Crespillo; Moira Allison; Harry Hemingway; John G Cleland; John J V McMurray; Kazem Rahimi Journal: Lancet Date: 2017-11-21 Impact factor: 79.321